MarketCapExport financials
Provention Bio (PRVB)
The export includes the complete available history of financial statements and ratios. Numbers are provided in full, without million or billion abbreviations, in their original reporting units.
CSV downloads as a ZIP archive with one file for each report and frequency.
Facebook
X
Telegram
Provention Bio Income Statement 2022-2011 | PRVB
Annual Income Statement Provention Bio
| 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
Market Cap |
1.79 B | 355 M | 889 M | 607 M | 39.7 M | - | - | - | - | - | - | - |
Shares |
74.7 M | 63.1 M | 52.5 M | 40.7 M | 22.4 M | 9.37 M | 7.64 M | - | - | - | - | - |
Historical Prices |
23.9 | 5.62 | 16.9 | 14.9 | 1.77 | - | - | - | - | - | - | - |
Net Income |
-114 M | -114 M | -98.6 M | -43.3 M | -26.5 M | -9.13 M | -165 K | - | - | - | - | - |
Revenue |
12.9 M | 1.4 M | - | - | - | - | - | - | - | - | - | - |
Operating Income |
-128 M | -116 M | -99.7 M | -44.4 M | -26.8 M | -9.14 M | -165 K | - | - | - | - | - |
Interest Expense |
1.04 M | - | - | - | - | - | - | - | - | - | - | - |
EBITDA |
-128 M | -115 M | -99.7 M | -44.4 M | -26.8 M | -9.14 M | -165 K | - | - | - | - | - |
Operating Expenses |
141 M | 117 M | 99.7 M | 44.4 M | 26.8 M | 9.14 M | 165 K | - | - | - | - | - |
General and Administrative Expenses |
64.1 M | 47.3 M | 33.3 M | 8.01 M | 4.16 M | 1.46 M | 165 K | - | - | - | - | - |
Annual performance
Select metrics to display
All numbers in USD currency
Quarterly Income Statement Provention Bio
| 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Shares |
- | 83.1 M | 64.7 M | 63.4 M | 63.4 M | 63.4 M | 63.4 M | 62.3 M | 56.5 M | 56.3 K | 49.2 K | 47.7 K | 47.7 M | 40.5 M | 37.4 M | 37.4 M | 37.4 M | 32 M | 10 M | 10 M | 10 M | 10 M | 9.47 M | - | 7.64 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Net Income |
- | -28.6 M | -29.7 M | -22 M | - | -27 M | -29.1 M | -32.4 M | - | -31.3 M | -22.1 M | -12.6 M | - | -9.77 M | -12 M | -11 M | - | -5.39 M | -10.3 M | -5.06 M | - | -1.36 M | -4.04 M | - | -165 K | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Revenue |
- | 756 K | 746 K | 580 K | - | 678 K | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Operating Income |
- | -29.1 M | -29.8 M | -29.1 M | - | -27.1 M | -30.2 M | -32.5 M | - | -31.4 M | -22.8 M | -12.9 M | - | -9.97 M | -12.3 M | -11.3 M | - | -5.41 M | -10.2 M | -5.04 M | - | -1.38 M | -3.99 M | - | -165 K | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Interest Expense |
- | 255 K | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
EBITDA |
- | -29 M | -29.6 M | -28.9 M | - | -27 M | -30.1 M | -32.4 M | - | -31.4 M | -22.8 M | -12.9 M | - | -9.97 M | -12.3 M | -11.3 M | - | -5.41 M | -10.2 M | -5.04 M | - | -1.38 M | -3.99 M | - | -165 K | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Operating Expenses |
- | 29.8 M | 30.6 M | 29.7 M | - | 27.8 M | 30.2 M | 32.5 M | - | 31.4 M | 22.8 M | 12.9 M | - | 9.97 M | 12.3 M | 11.3 M | - | 5.41 M | 10.2 M | 5.04 M | - | 1.38 M | 3.99 M | - | 165 K | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
General and Administrative Expenses |
- | 13.5 M | 14 M | 12.3 M | - | 10 M | 13.2 M | 12.8 M | - | 9.75 M | 7.76 M | 3.78 M | - | 2.65 M | 1.71 M | 1.24 M | - | 1.27 M | 1 M | 653 K | - | 488 K | 256 K | - | 165 K | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Quarterly performance
Select metrics to display
All numbers in USD currency
The income statement is one of the three key financial reports of a company Provention Bio (alongside the balance sheet and the cash flow statement). It shows how the company makes money and what its expenses are:
- How much revenue the company earned
- How much it spent on production, personnel, marketing, taxes, etc.
- What profit remained in the end
Analyzing the income statement helps an investor understand whether the business generates stable and growing profits, how effectively the company controls its expenses, and whether it is capable of generating income in the future. Additionally, this analysis shows how the company copes with crises and economic cycles, and allows assessing the potential for stock price growth and dividend payments.
Features- The income statement may include both recurring and one-time items (for example, profit from the sale of assets). It is necessary to separate core metrics from one-off events for accurate analysis.
- Companies often publish interim reports (e.g., quarterly), which allows for more timely tracking of trends.
- A combined analysis of the income statement with the balance sheet and cash flow statement provides a comprehensive view of the company’s financial health.
Reports on the profits and losses of other stocks in the Biotechnology industry
| Issuer | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|
 |
Innate Pharma S.A.
IPHA
|
$ 1.54 | 1.98 % | $ 138 M |  France |
 |
Seneca Biopharma, Inc.
SNCA
|
- | -1.19 % | $ 28.7 M |  USA |
 |
BioMarin Pharmaceutical
BMRN
|
$ 57.1 | -0.14 % | $ 11 B | USA |
 |
Matinas BioPharma Holdings
MTNB
|
$ 1.19 | -4.03 % | $ 6.51 M | USA |
 |
Enanta Pharmaceuticals
ENTA
|
$ 11.24 | -2.01 % | $ 240 K | USA |
 |
SIGA Technologies
SIGA
|
$ 3.14 | -3.83 % | $ 225 M | USA |
 |
Milestone Pharmaceuticals
MIST
|
$ 0.68 | -7.49 % | $ 72.2 M |  Canada |
 |
Kiniksa Pharmaceuticals, Ltd.
KNSA
|
$ 94.9 | -3.91 % | $ 7.04 B | USA |
 |
Lipocine
LPCN
|
$ 1.59 | -7.85 % | $ 8.66 M | USA |
 |
PTC Therapeutics
PTCT
|
$ 64.12 | -1.4 % | $ 5.1 B | USA |
 |
Seres Therapeutics
MCRB
|
$ 1.55 | -8.75 % | $ 13.7 M | USA |
 |
Madrigal Pharmaceuticals
MDGL
|
$ 432.48 | -0.07 % | $ 9.7 B | USA |
 |
CEL-SCI Corporation
CVM
|
$ 1.41 | 4.07 % | $ 11.3 M | USA |
 |
Inventiva S.A.
IVA
|
$ 3.95 | 2.73 % | $ 236 M | France |
 |
MeiraGTx Holdings plc
MGTX
|
$ 9.62 | 1.37 % | $ 774 M | USA |
 |
Processa Pharmaceuticals
PCSA
|
$ 1.86 | -4.62 % | $ 2.44 M | USA |
 |
Eton Pharmaceuticals
ETON
|
$ 67.5 | 4.9 % | $ 1.82 B | USA |
 |
IDEAYA Biosciences
IDYA
|
$ 31.72 | -0.97 % | $ 2.81 B | USA |
 |
Protalix BioTherapeutics
PLX
|
$ 2.86 | 11.28 % | $ 225 M |  Israel |
 |
Lantern Pharma
LTRN
|
$ 0.47 | -22.86 % | $ 5.12 M | USA |
 |
Foghorn Therapeutics
FHTX
|
$ 1.89 | -7.35 % | $ 119 M | USA |
 |
Ocugen
OCGN
|
$ 0.95 | -2.45 % | $ 297 M | USA |
 |
Oncolytics Biotech
ONCY
|
$ 0.38 | -5.64 % | $ 36.4 M | Canada |
 |
Minerva Neurosciences
NERV
|
$ 2.47 | -6.08 % | $ 20.9 M | USA |
 |
Kamada Ltd.
KMDA
|
$ 8.09 | 4.93 % | $ 466 M | Israel |
 |
Neurocrine Biosciences
NBIX
|
$ 169.08 | 0.13 % | $ 16.8 B | USA |
 |
Nanobiotix S.A.
NBTX
|
$ 32.8 | 2.4 % | $ 1.57 T | France |
 |
Mereo BioPharma Group plc
MREO
|
$ 0.3 | 1.66 % | $ 239 M |  Britain |
 |
Maravai LifeSciences Holdings
MRVI
|
$ 7.86 | -2.31 % | $ 1.13 B | USA |
 |
Lexicon Pharmaceuticals
LXRX
|
$ 1.84 | 0.82 % | $ 668 M | USA |
 |
Moleculin Biotech
MBRX
|
$ 8.01 | -7.51 % | $ 9.49 M | USA |
 |
Nurix Therapeutics
NRIX
|
$ 15.89 | -1.58 % | $ 1.38 B | USA |
 |
Nkarta
NKTX
|
$ 1.36 | -14.78 % | $ 101 M | USA |
 |
MacroGenics
MGNX
|
$ 2.42 | 3.42 % | $ 153 M | USA |
 |
Protagonist Therapeutics
PTGX
|
$ 136.18 | 0.2 % | $ 8.66 B | USA |
|
Nuvation Bio
NUVB
|
$ 4.22 | -3.1 % | $ 1.44 B | USA |
 |
Novo Nordisk A/S
NVO
|
$ 40.6 | -1.88 % | $ 180 B |  Danmark |
 |
Marker Therapeutics
MRKR
|
$ 0.95 | -3.87 % | $ 14.5 M | USA |
 |
NextCure
NXTC
|
$ 5.97 | -4.78 % | $ 17 M | USA |
 |
Rocket Pharmaceuticals
RCKT
|
$ 2.46 | -2.96 % | $ 273 M | USA |
 |
PMV Pharmaceuticals
PMVP
|
$ 1.22 | -2.8 % | $ 64.1 M | USA |
 |
Olema Pharmaceuticals
OLMA
|
$ 7.29 | -1.02 % | $ 634 M | USA |
 |
Kymera Therapeutics
KYMR
|
$ 136.45 | -1.74 % | $ 11.5 B | USA |
 |
Oragenics
OGEN
|
$ 0.35 | -1.47 % | $ 755 K | USA |
 |
Ovid Therapeutics
OVID
|
$ 2.8 | -1.75 % | $ 365 M | USA |
 |
Passage Bio
PASG
|
$ 3.81 | 11.08 % | $ 12.2 M | USA |
 |
Vaxcyte
PCVX
|
$ 66.44 | -1.61 % | $ 9.04 B | USA |
 |
Relay Therapeutics
RLAY
|
$ 19.81 | -2.87 % | $ 3.4 B | USA |
 |
Precigen
PGEN
|
$ 4.51 | -4.76 % | $ 1.41 B | USA |
 |
Avidity Biosciences
RNA
|
$ 8.23 | -1.79 % | $ 1.13 B | USA |